Vericel, MediWound climb on FDA's expanded approval for skin treatment

Vericel

15/08/2024 21:59

** Shares of Vericel  VCEL.O  rise ~2% to $47.05, MediWound
 MDWD.O  up ~1.8% at $18.50; in aftermarket trade
    ** Therapy developers say the U.S. FDA approved use of
NexoBrid medicine in pediatric patients with burns, for the
removal of dead skin  
    ** The enzymatic agent was initially approved in 2022 for
treatment in adults
    ** MDWD developed NexoBrid while VCEL holds an exclusive
license for North American rights to the treatment
    ** Up to last close, VCEL up 29.6%, MDWD up 78.7% YTD

    

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))